CD163 and rheumatoid arthritis: Analysis of patients with RA with follow-up clinical data demonstrated that higher baseline expression of CD206+CD163+CD40+ predicted a greater response to treatment at 1-year follow-up compared to those with minimal response or flare (Fig. 2C).